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Abstract
Background: Titanium dioxide (TiO2) is produced at high volumes and applied in many consumer and food
products. Recent toxicokinetic modelling indicated the potential of TiO2 to accumulate in human liver and spleen
upon daily oral exposure, which is not routinely investigated in chronic animal studies. A health risk from nanosized
TiO2 particle consumption could not be excluded then.
Results: Here we show the first quantification of both total titanium (Ti) and TiO2 particles in 15 post-mortem
human livers and spleens. These low-level analyses were enabled by the use of fully validated (single particle)
inductively coupled plasma high resolution mass spectrometry ((sp)ICP-HRMS) detection methods for total Ti and
TiO2 particles. The presence of TiO2 in the particles in tissues was confirmed by Scanning Electron Microscopy with
energy dispersive X-ray spectrometry.
Conclusions: These results prove that TiO2 particles are present in human liver and spleen, with ≥24% of nanosize
(< 100 nm). The levels are below the doses regarded as safe in animals, but half are above the dose that is deemed
safe for liver damage in humans when taking into account several commonly applied uncertainty factors. With
these new and unique human data, we remain with the conclusion that health risks due to oral exposure to TiO2
cannot be excluded.
Keywords: Titanium dioxide, Quantification, Human liver, Human spleen, Tissue level, Nanoparticle, Risk assessment,
Sp-ICP-HRMS
Background
Titanium dioxide (TiO2) is produced as titanium white
at high production volumes, up to 6 million tons per
year [1]. It is incorporated in many products, such as in
food (additive E171), toothpaste, supplements and medi-
cines, as well as in applications like paints, plastics, and
cosmetics [1]. Food grade TiO2 contains a fraction of
particles in the nanosize range, which is around 10%
number-based [2, 3]. No acceptable daily intake (ADI)
for oral ingestion of TiO2 has been derived in the past due
to the absence of observed toxic effects in the available
chronic rodent study [4], the generally assumed negligible
uptake of TiO2 following ingestion [5], and the assumed
insolubility and inertness of the material [6, 7]. Recent hu-
man volunteer studies, however, show elevated blood Ti
levels (and indications of TiO2 particles) 6 h after
ingestion of food grade TiO2 [8], confirming earlier
reports of increased blood Ti-levels after ingestion of
160 nm and 380 nm TiO2 particles [9]. Upon evaluating
food grade TiO2, the European Food Safety Agency
(EFSA) acknowledged that TiO2 is absorbed after oral
application, albeit to a low extent, and transported to
various organs [10]. Recently, very low oral (0.02 and
0.6%) absorption of TiO2 nanoparticles has been shown
in rats, with a retention of these particles in mainly the
liver and spleen [11, 12]. This calls for (nano)particle
biokinetic studies in humans [13].* Correspondence: minne.heringa@rivm.nl1National Institute for Public Health and the Environment (RIVM), Bilthoven,
The Netherlands
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Toxicokinetic modelling of TiO2 levels in human
organs, based on animal studies and accounting for
accumulation, has recently led to the conclusion that a
human health risk from the oral intake of TiO2 nanopar-
ticles cannot be excluded [14]. Although most accumula-
tion was seen in spleen, in the final risk assessment, a
potential risk was found for the liver. It remained uncer-
tain whether the modelled levels of TiO2 nanoparticles
for human liver and spleen are accurate, which is best
verified by measurements. Although total-Ti has been
detected before in human tissues like liver and spleen
[15, 16], there currently are no data on the presence of
TiO2 (nano)particles in human tissues from people with-
out titanium implants [17, 18]. Here, we present the first
quantitative measurements of particles, both in size and
concentration, in post-mortem liver and spleen of 15
human subjects (see Table 1) with a corresponding
assessment of the risks that can potentially be associated
with the observed total Ti and TiO2 particle concentra-
tions in these tissues.
Methods
Firstly, we determined the total-Ti content in human liver
and spleen samples using a fully validated procedure that
included the acid digestion of the formaldehyde-fixed
homogenized human tissues and ICP-HRMS detection
(Peters RJB, Undas A, Memelink J, van Bemmel G,
Munniks S, Bouwmeester H, et al.: Development and
validation of a method for the detection of titanium
dioxide particles in human tissue, submitted). Next, a new,
independent subsample was prepared to quantitatively
determine the presence of TiO2 particles in these tissues.
For this, highly sensitive and selective spICP-HRMS was
used [2, 19–21]. The enzymatic and gentle chemical sample
clean-up and detection method for Ti in tissues and organs
was recently fully validated (Peters RJB, Undas A, Meme-
link J, van Bemmel G, Munniks S, Bouwmeester H, et al.:
Development and validation of a method for the detection
of titanium dioxide particles in human tissue, submitted).
The sample preparation is known not to affect the presence
and size of particles [2].
Samples and sample preparation
The inertness of TiO2 allowed the use of livers (15) and
spleens (15) obtained from bodies that were donated to
the Department of Anatomy of the University Medical
Centre Utrecht for educational and research purposes
(Table 1). All ethical regulations concerning the use of
these organs were followed, and approval for this spe-
cific scientific use was obtained from the board of Uni-
versity Medical Center Utrecht. The bodies, 6 men and
9 women who died at the age of 56 to 104 years, had
been fixed in 4% formaldehyde. From these persons writ-
ten informed consent was obtained during life that
allowed the use of their entire bodies for educational
and research purposes. While there is no information
about their diets, it is known that all persons involved
are of Caucasian ethnicity except one who was of Asian
ethnicity. All have lived in the Netherlands their entire
life and it is therefore assumed that most followed a
Dutch diet [22]. Of the 15 persons involved, 2 received
titanium implants during their lifetime. For sample prep-
aration, each organ was cut into small pieces and
grinded to a size of 0.5–1 mm diameter. To investigate
potential sample contamination, all materials that had
been in contact with the organs were collected. The
total-Ti concentrations in these materials or released by
these materials were determined. The average of the
analytical results of those blank materials were calcu-
lated and subtracted from the sample results if they were
above the limit of detection (LOD).
Determination of total-Ti content
An analytical sample of 1 g was collected from each
grinded and homogenized sample and brought into a per-
fluoroalkoxy (PFA) microwave digestion tube to which
6 mL of nitric acid (70% HNO3) and 2 mL of hydrofluoric
acid (40% HF), were added. All subsamples were digested
for 55 min in a MARS microwave system (CEM Corpor-
ation, Matthews, NC, USA). The temperature program
was as follows: at 1600 W power from 20 to 120 °C in
15 min, then to 160 °C in 10 min, and then to 210 °C in
30 min and hold for 1 min. Following digestion and cool-
ing to room temperature, ultra-pure water was added to a
total volume of 50 mL. The extracts were shaken manu-
ally, diluted 2 times, and analysed with ICP-HRMS.
Table 1 Overview of human subjects involved in this study
Subject number Gender (F/M) Age (years) Ethnicity Ti implants
1 F 80 Caucasian No
2 F 92 Caucasian No
3 M 64 Caucasian Yes
4 M 86 Caucasian No
5 M 87 Caucasian No
6 M 79 Caucasian No
7 F 94 Asian No
8 F 77 Caucasian No
9 F 86 Caucasian No
10 M 77 Caucasian Yes
11 F 104 Caucasian No
12 F 96 Caucasian No
13 F 91 Caucasian No
14 F 94 Caucasian No
15 M 56 Caucasian No
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Quantification was based on ionic titanium standards di-
luted in the same acidic matrix as the samples. Method
blanks were determined by performing the complete pro-
cedure, however, without the addition of a sample. The
total-Ti content in the blanks was below the method
LOD.
Determination of TiO2 particles
For the determination of particle-TiO2, a digestion pro-
cedure is followed to liberate the particles. This diges-
tion procedure consists of two steps. In the first step,
the tissue in the formaldehyde-fixed sample is depoly-
merized, while in the second step, a standard enzymatic
digestion is performed. An analytical sample of 200 mg
was collected from the grinded subsamples and brought
into a 12-mL PE tube. In the first step, 4 mL of the di-
gestion buffer was added and the sample was vigorously
vortexed for 30 s. The digestion buffer was prepared by
dissolving 300 mg of Tris buffer, 92.5 mg EDTA, 5 mg
SDS and 3 g NaCl in 100 mL of Milli-Q water. Next, 4 g
of glycine are added to the solution and mixed with a
magnetic stirrer until complete dissolution. This solution
was diluted with Milli-Q water to a final volume of
250 mL.
The tube was heated for 3 h. at 100 °C to depolymerize
the formaldehyde-fixed tissue. In the second step, and
after cooling to room temperature, 910 μL of proteinase K
(2.5 mg/ml) was added. The tube was incubated for 16 h.
at 37 °C in a shaking water bath. After cooling to room
temperature, the digest was diluted with ultra-pure water
and analyzed using spICP-HRMS.
Instrumental analysis with ICP-HRMS
A Thermo Finnigan Element 2 (Thermo Fisher Scien-
tific GmbH, Bremen, Germany), a sector-field based
high resolution ICP-MS, was used to measure total-Ti
in acidic extracts in standard mode and TiO2 parti-
cles in single-particle mode (also called time resolved
analysis mode). Single-particle ICP-HRMS is a
method for the detection and characterization of
(nano-)particles [19, 21]. The Thermo Finnigan Elem-
ent 2 was operated at a forward power of 1300 W
and the argon gas flows were at the following set-
tings; plasma, 15.4 L/min; nebulizer, 1.063 L/min;
auxiliary, 1.2 L/min. The sample flow rate to the
nebulizer was set at 0.5 mL/min. Data acquisition was
done in standard mode and in time resolved analysis
mode with titanium measured at m/z 46.95 in
medium resolution mode to avoid interferences from
36Ar12C, 32S16O and 48Ca. In standard and time re-
solved mode the dwell time was 250 and 2 ms re-
spectively, with a total acquisition time of 60 s. The
transport efficiency was determined by the analyses of
a 50 ng/L diluted aqueous RM8013 (60 nm gold
nanoparticle) suspension under the same instrumental
conditions as the samples but monitoring m/z 197 for
gold. Finally, single-particle data were exported as csv
file and processed in a dedicated spreadsheet for the
calculation of particle sizes, particle size distributions,
and particle number and mass concentrations. Details
about this spreadsheet and the calculation of the pa-
rameters can be found elsewhere [19]. Method blanks
were determined by performing the complete proced-
ure, however, without the addition of a sample. The
mass-based TiO2 particle concentrations in the blanks
were below the method LOD. Since the blanks of the
sampling materials were below the LOD of the total-
Ti method they were not involved in the particle
analysis.
LOD
For the total-Ti determination the LOD is calculated as
3 times the standard deviation in the results of a blank
sample or a sample with a total-Ti content close to the
expected LOD. This sample is analysed on each of the
validation days. The LOD is calculated as follows:
LOD ¼ 3
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Pk
i¼1 yi−mð Þ2
k−1
s
where k is the number of samples, yi is the result of a
single sample and m is average result of the single
samples.
For particle-TiO2 there are two LOD values, one for
the number- and mass-based concentration (LODC), and
one for particle size (LODS). LODC equals the minimum
number of particle peaks in the time scan that differenti-
ates a sample from a blank. A way to determine LODC
is by the IUPAC recommended approximation (Poisson)
described as [23],
LODC ¼ 3:29
ﬃﬃﬃﬃ
N
p
þ 2:72
where N is the number of particle peaks observed in the
time scan of a blank. The particle number LODC can be
converted into mass units if the size and density of the
particle are known. The determination of the LODS is
described by Lee et al. and can be estimated as follows
[24],
LODS ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
6 3σm
R f a  ρ π
3
s
where σm is the standard deviation in the background
noise in the time scan, R is the ICP-MS response (cps/
μg), fa is the mass fraction of analysed element in the
nanoparticle and ρ is the density of the nanoparticle
material (g/cm3). The upper size limit of detection is es-
timated to be around 1500 nm.
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Confirmation of TiO2 particles wit SEM-EDX
Two subsamples of the grinded sample material of
both the livers and the spleens were studied using
scanning electron microscopy with energy dispersive
X-ray detection (SEM-EDX) to confirm the presence
of TiO2 particles in human liver and spleen. The
samples with the highest TiO2 concentrations (as de-
termined with ICP-HRMS) were selected for confirm-
ation with SEM-EDX. Typically, subsamples of > 100
tissue grains were collected on a sampling stub and
dried to remove water. These subsamples were ana-
lysed with a high resolution field emission gun scan-
ning electron microscopy in combination with energy
dispersive X-ray analysis (FEG-SEM/EDX). Approxi-
mately 500 images for each sample were viewed at
different magnifications (5.000–100.000 X) to identify
TiO2 particles. For each sample, approximately 10
TiO2 particles (single nanoparticles as well as aggre-
gates/agglomerates) were detected. The surface of the
grains was systematically analysed for TiO2 particles
using the backscattered electron imaging mode. After
detection of particles in a field of view, X-ray spectra
from the detected particle and surrounding matrix
were acquired to determine the identity. Subsequently,
plasma-ashing was applied to remove the lipid frac-
tion and obtain a sharper image of the TiO2 particle.
Results
All tissue levels are given as wet organ weights as
obtained after fixation in formaldehyde.
Total Ti measurements
As shown in Table 2, the total-Ti content in the liver
ranged from 0.02 to 0.09 mg Ti/kg tissue with an aver-
age value of 0.04 ± 0.02 mg Ti/kg tissue1. For spleen, the
total-Ti content ranged from 0.02 to 0.4 mg Ti/kg tissue
with an average value of 0.08 ± 0.1 mg Ti/kg tissue1.
In the sparsely available literature on human data,
liver and spleen concentrations ranging between 0.2
and 1.9 mg Ti/kg tissue have been detected. These
Table 2 Ti and TiO2 particles in human (post mortem 4% formaldehyde fixed) liver and spleen
Total Ti TiO2 (Particles) Ti in particles
a Total Ti TiO2 (Particles) Ti in particles
a
Human Tissue size range number of
particles
min - max Tissue size range number of
particles
min - max
subject mg/kg nm 109 /kg tissue mg/kg tissue mg/kg nm 109 /kg tissue mg/kg tissue
1 Liver 0.04 85–320 2.3–7.2 0.01–0.04 Spleen 0.1 90–580 5.7–18 0.06–0.2
2 Liver 0.09 90–440 6.6–21 0.08–0.3 Spleen 0.4 90–420 18–56 0.1–0.4
3 Liver < LODt < LODs < LODn < LODc Spleen 0.02 85–370 1.2–3.8 0.01–0.04
4 Liver 0.05 85–550 1.4–4.4 0.03–0.1 Spleen 0.09 85–320 2.8–8.8 0.01–0.02
5 Liver < LODt < LODs < LODn < LODc Spleen 0.03 85–520 1.5–4.7 0.02–0.07
6 Liver 0.03 85–380 2.1–6.6 0.01–0.04 Spleen 0.02 85–350 1.3–4.1 0.01–0.04
7 Liver < LODt 85–370 1.3–4.1 0.01–0.02 Spleen 0.02 < LODs <LODn < LODc
8 Liver 0.02 < LODs < LODn < LODc Spleen < LODt < LODs <LODn < LODc
9 Liver < LODt < LODs < LODn < LODc Spleen 0.2 85–410 9.3–29 0.08–0.3
10 Liver < LODt < LODs < LODn < LODc Spleen 0.02 85–360 2.1–6.6 0.01–0.04
11 Liver 0.04 85–450 2.6–8.1 0.02–0.07 Spleen 0.03 90–420 3.2–10 0.02–0.07
12 Liver 0.02 < LODs < LODn < LODc Spleen 0.04 90–720 2.1–6.6 0.05–0.2
13 Liver < LODt 90–440 1.0–3.1 0.03–0.1 Spleen 0.02 90–390 2.3–7.2 0.03–0.10
14 Liver < LODt < LODs < LODn < LOD Spleen 0.03 90–430 2.7–5.3 0.03–0.1
15 Liver < LODt < LODs < LODn < LODc Spleen 0.04 90–500 2.4–7.5 0.03–0.1
n > lod 7 7–7 7–7 7–7 14 13–13 13–13 13–13
average 0.04b 86–421 2–8 0.03–0.1 0.08 c 88–445 4–13 0.04–0.1
mode 0.04 85–440 – 0.01–0.04 0.02 85–420 2–7 0.01–0.04
stdev 0.02 2–74 2–6 0.02–0.1 0.1 3–110 5–15 0.03–0.11
min 0.02 85–320 1–3 0.01–0.02 0.02 85–320 1–4 0.01–0.02
max 0.09 90–550 7–21 0.08–0.3 0.4 90–720 18–56 0.1–0.4
Particle TiO2 concentrations are reported as measured (min) and after correction for the analytical recovery (max). All concentrations are corrected for total
concentrations in blanks (0.05 mg/kg). LODt (total-Ti) = 0.01 mg/kg; LODs (size) = 85 nm; LODn (number) = 0.8 × 109/kg; LODc (calculated Ti in particles) =
0.005 mg/kg; acalculated Ti in particle, calculated according to Laborda et al. [21] and Peters et al. b if calculated with ½ LOD for samples below LOD, average
total-Ti = 0.02 mg/kg;cif calculated with ½ LOD for samples below LOD, average total-Ti = 0.07 mg/kg
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concentrations have been measured using X-ray fluor-
escence and neutron activation analysis, while we
used HR-ICPS [25, 26].
The blank-corrected limit of detection (LOD)total Ti
was 0.01 mg/kg tissue, while the analytical recovery for
total-Ti was 112 ± 34%, which is in the range of accepted
analytical standards [20]. None of the specific steps in
the tissue and sample preparation contributed to the
blank total-Ti. Two human subjects carried a titanium
implant, the total-Ti content in liver and spleen of these
subjects was comparable to those observed in the liver
and spleen in other subjects.
Particle measurements
The presence of TiO2 particles in the tissues is
evidenced by the characteristic spikes in the time scans
of the spICP-HRMS analysis of liver and spleen samples
(Fig. 1a, b). TiO2 particles were detected in 7/15 liver
and 13/15 spleen samples (Table 2). The smallest TiO2
particle that can be detected with this method (LODsize)
in these tissues is 85 nm. The number-based TiO2
particle size distributions in liver and spleen were
comparable and had a size range of 85–550 and 85–720,
respectively (Table 2 and Fig. 1c). SpICP-HRMS does
not allow a further characterisation of the particles being
Fig. 1 TiO2 particles in human (post mortem) liver and spleen. Time scans of the spICP-HRMS analyses of a liver sample (a) and spleen sample
(b). The number of spikes in the time scan is directly proportional to the number of particles in the sample. The signal height of the peaks is
directly proportional to the particle’s mass from which the equivalent spherical particle size is calculated [22, 23]. c The calculated
number-based particle size distribution (left axis and dark colours) and the calculated mass-based particle size distribution (right axis and
light colours). Since the particle size distribution in liver (red bars) and spleen (blue bars) are very similar, they are stacked
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present as agglomerates, aggregates or primary particles.
In the tissues, 24% of the TiO2 particles in the number-
based size distribution was < 100 nm, but this fraction
may be underestimated considering the LODsize of
85 nm.
The TiO2 particle mass concentration in liver ranged
from 0.01 to 0.3 mg Ti/kg tissue (1.0 × 109 to 21 × 109
TiO2 particles/kg tissue) (Table 2). In spleen, this con-
centration ranged from 0.01 to 0.4 mg Ti/kg tissue
(1.2 × 109 to 56 × 109 TiO2 particles/kg tissue). The
LODparticle-number in the tissue matrix is 0.8 × 10
9 parti-
cles per kg tissue. The analytical recovery of TiO2 parti-
cles by enzymatic digestion of the matrix is 32 ± 7%.
This low analytical recovery is in accordance with best
international practices for this sample preparation and
detection technique [27]. Because of the low analytical
recovery, the Ti concentration of the particles is pre-
sented both as a minimum (not corrected for analytical
recovery), and a maximum (corrected for analytical re-
covery) (see Table 2).
The total-Ti values are in general within this Ti con-
centration range in the particles, Furthermore, tissues
with high total-Ti concentrations also contained high
TiO2 particle concentrations, and vice versa. Based on
the maximum Ti concentration values in particles, on
average minimally 51% (liver) and 67% (spleen) of total
Ti is present in these tissues as particle. Taking into
account the analytical recovery (32 ± 7%) and the LODsize
(85 nm) for the particles measurements, we assume all
total Ti is present as particles.
We did not observe a correlation in the abundance of
the TiO2 particles in liver and spleen from the same sub-
jects, while this would be expected based on the shared
external exposure. The reason for this lack of correlation
may be related to inter-individual differences in the vari-
ous involved biodistribution processes.
Lastly, small tissue grains of liver and spleen from two
subjects were analysed using SEM-EDX to visualize the
TiO2 particles. As shown in Fig. 2, the observed particles
are composed of Ti and oxygen and are present as an
aggregate or agglomerate, consisting of smaller primary
particles of 75–150 nm. Presence of Ti was also con-
firmed semi-quantitatively by EDX analysis in dry-ashed
liver and spleen samples (Fig. 2d).
Together, these analyses show that approximately all
TiO2 is present as particles in human liver and spleen,
with sizes ranging 85–550 and 85–720, respectively
(upper size limit of detection was > 1.5 μm). Probably
also smaller particles are present, however these cannot
be detected with the current methods. The SEM analysis
of the particles suggests that the larger particles consist
of smaller primary particles. Therefore, for the purpose
of risk assessment, we assume that all Ti is ultimately
present as TiO2 nanoparticles.
Risk assessment
In a next step, the total TiO2 levels in liver and
spleen were compared to the toxicologically safe tis-
sue levels for TiO2 (0.14 mg/kg for spleen and
a b
c d
Fig. 2 SEM characterization of detected TiO2 particles in a dried liver sample. a The secondary electron microscope image shows a TiO2
agglomerate below the surface of the liver tissue (arrow). b The backscattered electron image reveals the spherically shaped primary particles
within the agglomerate (arrow), with diameters between 75 and 150 nm; (c) illustrates the path of the EDX line scan across the aggregate in the
same image at higher magnification; (d) demonstrates the presence of TiO2 based on the corresponding increase of response for Ti (red line) and
oxygen (blue line) at the position of the particle. This forms a clear indication that the detected particle is indeed TiO2
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0.008 mg/kg for liver), as reported earlier [14]. For
liver, the measured TiO2 concentrations are all below
the level where effects occurred in animals, which
were the occurrence of liver edema and liver enzyme
level changes. However, the seven measurements
>LOD are above the level at which effects may occur
in humans (Fig. 3). For the estimation of the safe
level in humans, interspecies differences were consid-
ered and sensitive subpopulations were accounted for,
which would include children, elderly, and diseased
people (see also Additional file 1). It can therefore
not be excluded that the observed liver levels lead to
adverse effects in humans, such as a liver functioning
less well, leading to e.g. less detoxification of sub-
stances in the blood, and less albumin production.
For spleen, it is unlikely that adverse effects will
occur in humans as the measured levels are distrib-
uted around the estimated safe levels (please note
that in the key toxicological study [28], no adverse ef-
fects were reported, thus the highest tested dose was
used here [14] (see also Additional file 2).
Discussion
The TiO2 particles observed in the human liver and
spleens may have entered the body through dermal,
inhalatory or oral exposure. No data on exposure, and
thus neither on exposure route, of the subjects included
in this study during life is available. However, dermal up-
take of TiO2 particles is unlikely, as TiO2 particles do
not penetrate the (intact) human skin [17, 29]. It is likely
that inhalatory uptake can be neglected as the chance is
small that these people (all) had occupations with TiO2
exposure through air. In addition, the estimated maximal
non-occupational exposure through this route is 4.5 μg
Ti/day (with an average of 0.75 μg TiO2/day; based on
the Ti concentrations in non-occupational settings of
0.01–0.1 μg/m3) [30]. Furthermore, most of these in-
haled TiO2 particles are eliminated from the lungs by
mucociliary clearance in the ciliated part of the lungs,
and subsequently swallowed, as seen in some studies
[31, 32]. Probably, most human subjects followed a West
European diet and used toothpaste, which may result in
a mean oral intake of 0.06–5.5 mg TiO2/kg body weight/
day [3, 10, 33, 34]. Recent human volunteer studies indi-
cate the systemic uptake following ingestion of TiO2
particles [8, 9]. Strikingly, the size range of the TiO2 par-
ticles in the human livers and spleens (i.e. 86–421 and
88–445 nm, respectively) falls within that of the TiO2
particles in food products (30–600 nm diameter [2]). In
conclusion, intestinal exposure, e.g. from food, tooth-
paste and supplements, but also from any inhaled and
swallowed particles, is the most likely source of the Ti
and TiO2 particles as found in the liver and spleens of
these 15 subjects. This justifies our comparison with safe
tissue levels derived from oral toxicity studies.
The current study shows that both the element Ti and
TiO2 particles are present in post mortem fixed human
liver and spleen and that health risks from liver damage
due to oral exposure to TiO2 still cannot be excluded,
especially in elderly people. Clearly, some issues as
Fig. 3 Observed liver and spleen concentrations compared to toxicological effect levels. Measured total Ti (expressed as TiO2 to enable
comparison, red diamonds) and TiO2 particle concentrations (blue ranges) in human liver and spleen are plotted against age, together with liver
or spleen concentrations that are relevant for risk assessment (black lines). Open diamonds and arrows represent the possible levels in the
samples where the Ti level was below the limit of detection (LOD). Measured particle concentrations are given as a range between the minimum
possible level (no correction for the analytical recovery) and the maximum possible level (corrected for the analytical recovery). The solid black
line represents the organ level at the No Observed Adverse Effect Level (NOAEL) in the animal study, i.e. the highest level at which no adverse
effect was observed. The dashed black line represents the organ level below which no effects are expected in humans, considering several
uncertainties in the animal data
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addressed in Heringa et al. [14] remain unresolved, like
the limitations in the toxicological data set and the
impact that different forms of TiO2, with different size
[35], surface properties or crystalline structure can have
on the observed toxicity. In addition, the available
organs for this study were, understandably, limited to rela-
tively older people and their TiO2 exposure and health
condition is not known. Recently, concern has been raised
on the potential contribution of TiO2 on tumor formation
in the intestine [36, 37]. More information on the adverse
effects of TiO2 particles, including potential effects on
liver as well as on potential carcinogenic induction and
promotion in the gastrointestinal tract, would reduce the
uncertainties in the current risk assessment.
Conclusion
Using two independent particle characterization tech-
niques, we unequivocally show the presence of TiO2
particles in (post mortem) human liver and spleen and
provide quantitative data on the total human organ
burden of TiO2 particles for the first time. Particles with
a size between 85 and 720 nm were found in tissue, of
which at least 24% was smaller than 100 nm. This
unique study thereby adds another critical piece to
the risk assessment puzzle for TiO2 (nano)particles,
showing that health risks related to liver damage
(i.e. liver edema and liver enzyme changes) due to
TiO2 particles still cannot be excluded.
Endnotes
1Values reported here are based on values above LOD,
excluding the values below LOD.
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